Phase 1b Clinical Trial Commences for Peosertive and Lutetium-177 Dotatate Combination in Pancreatic Neuroendocrine Tumors
Background
This trial is a Phase 1b study evaluating the combination of Peosertive (M3814) with Lutetium-177 Dotatate in patients with pancreatic neuroendocrine tumors. Current standard treatments include somatostatin analogs, targeted therapies, and radioligand therapy. Peosertive is a DNA-PK inhibitor that can disrupt DNA repair, potentially enhancing the effects of radiation.
Trial Design
The trial began in July 2021 and is currently closed to enrollment. As a Phase 1b study, it aims to assess the optimal dose, safety, and preliminary efficacy. The primary endpoints are dose-limiting toxicities and the safety profile. Participating patients receive Peosertive in addition to Lutetium-177 Dotatate.
Expected Outcomes
By blocking DNA repair pathways, Peosertive may prevent the repair of DNA damage caused by radioligand therapy, leading to increased cancer cell death. This could potentially improve the limited response rates observed with existing PRRT (peptide receptor radionuclide therapy).
Market Impact
Pancreatic neuroendocrine tumors are rare, but treatment options are limited. If this combination demonstrates positive clinical results, it could drive growth in the PRRT market and increase the pipeline value of DNA-PK inhibitor companies. Furthermore, as a public research initiative led by the NCI, early data may open the door for future partnerships with pharmaceutical companies.
This combination therapy, leveraging the synergy between a DNA-PK inhibitor and radioligand therapy, has the potential to increase the value of the PRRT market and present opportunities for future licensing revenue. Job seekers looking to enter the pharmaceutical and biotechnology fields should understand the latest combination strategies, and securing clinical data will enhance their competitiveness in the job market.
Source: ClinicalTrials.gov (api_ct)